Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable.
There is an urgent need to validate biomarkers and implement them in daily clinical practice. PRIME-CKD has a unique advantage to address this challenge as it builds on recent discoveries of new biomarkers to help guide optimal treatment to individual patients.